Literature DB >> 15583745

Effect of activated platelets on expression of cytokines in peripheral blood mononuclear cells - potential role of prostaglandin E2.

Torgun Waehre1, Jan Kristian Damås, Arne Yndestad, Kjetil Taskén, Turid M Pedersen, Camilla Smith, Bente Halvorsen, Stig S Frøland, Nils O Solum, Pål Aukrust.   

Abstract

Platelets may act as inflammatory cells. To study the effects of soluble and cell-bound platelet factors on the expression of several cytokines and related mediators in leukocytes, peripheral blood mononuclear cells (PBMC) were incubated with platelet-free supernatants from SFLLRN-activated platelet-rich plasma (PRP) or SFLLRN-activated PRP in itself. Our main findings were: (i) the gene expression of several chemokines and some cytokines were markedly increased by both activated PRP and supernatants, as also confirmed at the protein level for IL-6, IL-8 and MIP-1alpha; (ii) the selective protein kinase A type I (PKAI) antagonist Rp-8-Br-cAMP reduced this platelet-induced expression of IL-6, IL-8 and MIP-1alpha in PBMC, suggesting a role of cAMP/PKAI mediated mechanisms in this interaction; (iii) PGE(2) dose-dependently increased the release of IL-6, IL-8 and MIP-1alpha from PBMC mimicking the effect of activated platelets. Furthermore, activated platelets released comparable amounts of PGE(2), suggesting that platelet-derived PGE2 could interact with PBMC in co-cultures; (iv) IL-10 inhibited the platelet-inducing effect on IL-6, IL-8 and MIP-1alpha in PBMC, and notably, the addition PGE2 totally abolished this IL-10 effect suggesting that the suppressive effect of IL-10 on the plateletinduced activation of PBMC might at least partly involve PGE(2) related mechanisms. The present study supports a view of platelets as inflammatory cells, and suggests a potential role of platelet-derived PGE(2) in platelet-induced inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15583745     DOI: 10.1160/TH04-03-0146

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Peripheral blood mononuclear cells enhance the anabolic effects of platelet-rich plasma on anterior cruciate ligament fibroblasts.

Authors:  Ryu Yoshida; Martha M Murray
Journal:  J Orthop Res       Date:  2012-07-05       Impact factor: 3.494

Review 2.  Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications.

Authors:  R E Kast
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

3.  Combined Usefulness of the Platelet-to-Lymphocyte Ratio and the Neutrophil-to-Lymphocyte Ratio in Predicting the Long-Term Adverse Events in Patients Who Have Undergone Percutaneous Coronary Intervention with a Drug-Eluting Stent.

Authors:  Kyoung Im Cho; Soe Hee Ann; Gillian Balbir Singh; Ae-Young Her; Eun-Seok Shin
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

4.  Activated Platelets Induce an Anti-Inflammatory Response of Monocytes/Macrophages through Cross-Regulation of PGE2 and Cytokines.

Authors:  Bona Linke; Yannick Schreiber; Bettina Picard-Willems; Patrick Slattery; Rolf M Nüsing; Sebastian Harder; Gerd Geisslinger; Klaus Scholich
Journal:  Mediators Inflamm       Date:  2017-05-16       Impact factor: 4.711

5.  Relationship between the presence of left atrial thrombus in patients with mitral stenosis and platelet-to-lymphocyte ratio.

Authors:  Erdal Belen; Ender Özal; Hamdi Püsüroğlu
Journal:  Anatol J Cardiol       Date:  2015-11-18       Impact factor: 1.596

6.  Mid-arm muscle circumference: A significant factor of all-cause and cancer mortalities in individuals with elevated platelet-to-lymphocyte ratio.

Authors:  Pi-Kai Chang; Wei-Liang Chen; Li-Wei Wu
Journal:  PLoS One       Date:  2018-12-13       Impact factor: 3.240

Review 7.  Platelets in aging and cancer-"double-edged sword".

Authors:  Alessandra V S Faria; Sheila S Andrade; Maikel P Peppelenbosch; Carmen V Ferreira-Halder; Gwenny M Fuhler
Journal:  Cancer Metastasis Rev       Date:  2020-09-01       Impact factor: 9.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.